The in vitro and in vivo efficacy and drug-drug interactions of the novel semi-synthetic endoperoxide artemisone with standard antimalarials were investigated in order to provide the basis for the selection of the best partner drug.
Introduction
Artemisinin derivatives are the most potent and rapidly acting drugs against multidrug-resistant Plasmodium falciparum malaria and are currently being used in combination with other antimalarials. Artemisinin-based combination therapies are the WHO-recommended treatment policy for uncomplicated malaria 1 in countries where standard antimalarials are already ineffective due to drug resistance. 2 Artemisinins are increasingly being used in combination with standard antimalarials such as amodiaquine, sulfadoxine/pyrimethamine, mefloquine and lumefantrine, considerably reducing treatment times, the dose of artemisinins and the potential risk for selection and transmission of drug-resistant parasites. 2 -5 The superior advantage of artemisinin combination therapy has been demonstrated in Thailand, where the combination of mefloquine with artesunate is effective in areas of established mefloquine resistance, considerably delaying its progression and augmenting cure rates when compared with mefloquine alone. 6 Efficacy trials have also shown the superiority of artemisinin combination therapy when compared with monotherapy in areas of drug-resistant malaria in Africa. 7, 8 Furthermore, artesunate monotherapy therapeutic failures in non-immune individuals from Central Africa were associated with reduced in vitro susceptibility. 9, 10 In another study in French Guiana, in which artemether-lumefantrine is the recommended policy, a reduction in the level of in vitro susceptibility was associated with point mutations in the sarco/endoplasmic reticulum calcium-dependent ATPase (SERCA), possibly representing the first step towards clinical resistance.
11,12 Therefore, there is a pressing need for the discovery and development of novel, cheaper alternatives, including new artemisinin derivatives with efficacy against artemisinin-resistant parasites.
Artemisone is a new semi-synthetic 10-alkylaminoartemisinin that can be synthesized from dihydroartemisinin in a one-step process. 13 Artemisone shows increased antiplasmodial activity, improved in vivo half-life, improved oral bioavailability and metabolic stability, no neurotoxicity 14, 15 and is well tolerated in humans, 16 with a curative effect at dose levels at least half those of artesunate in Phase IIa trials in comparison with artesunate. 17 Thus, it is of particular urgency to assess the effect of combination of artemisone with other antimalarials.
As cheaper and more effective artemisinin derivatives are potentially incorporated into artemisinin combination therapy for the treatment of uncomplicated malaria, the aim of this study was to confirm that artemisone showed comparable or better activity than other members of its class and to provide the basis for the selection of the best partner drug for use as part of artemisinin combination therapy.
Materials and methods

Drugs
The following drugs were used: chloroquine diphosphate, quinine-HCl, pyrimethamine-HCl, amodiaquine, clindamycin and mefloquine-HCl (Sigma, Dorset, UK); tafenoquine and atovaquone (GSK, UK); lumefantrine (Novartis Pharma, Basel, Switzerland); artemisone (Bayer AG, Leverkusen, Germany) and artesunate (WHO/TDR, Geneva, Switzerland).
P. falciparum in vitro culture
All parasite clones, isolates and strains were acquired from MR4 (Malaria Research and Reference Reagent Resource Center, Manassas, VA, USA). Strains/isolates used in this study were: the drug-susceptible 3D7 clone of the NF54 isolate (unknown origin); the drug-susceptible strains FCR-8 (Gambia) and FCC2 (China); the chloroquine-resistant, pyrimethamine-resistant and cycloguanil-resistant K1 strain (Thailand); the chloroquineresistant and pyrimethamine-resistant FCR3 strain (Gambia); the chloroquine-resistant FCB strain (Colombia); and the chloroquine-resistant, pyrimethamine-resistant and cycloguanilresistant isolate Tm90C2A (Thailand). In vitro culture of P. falciparum was carried out following standard methods 18 with modifications as described previously. 19 In vitro parasite growth inhibition assays and in vitro drug -drug interactions In vitro parasite growth inhibition was assessed by the incorporation of [ 3 H]hypoxanthine based on the method used by Desjardins et al. 20 and modified as described previously. 19 In vitro interactions were examined by a modified fixed ratio method as described previously. 21 Stock drug solutions were prepared in 100% dimethylsulphoxide (DMSO) (Sigma) except for chloroquine which was dissolved at 10 mg/mL in distilled water. Amodiaquine, mefloquine, tafenoquine, quinine and pyrimethamine stocks were prepared at 10 mg/mL, artesunate and artemisone stocks freshly prepared at 10 mg/mL and atovaquone and lumefantrine stocks at 1 mg/mL. Artemisone (Drug A) plus second test drug (Drug B) solutions were prepared in assay medium at ratios of 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5 followed by 2-fold serial dilutions in assay medium of each ratio, allowing the IC 50 to fall approximately at the mid-point of the serial dilution of each drug alone. Fifty microlitres of P. falciparum (65-75% ring stage) culture at 0.5% parasitaemia or uninfected red blood cells (URBCs) was added to each well, reaching a final volume of 100 mL per well, a final haematocrit of 2.5% and final DMSO concentrations between 0.01 and 0.1%. Plates were incubated at 378C in a 5% CO 2 /95% air mixture for 24 h, at which point 20 mL (0. Lack of interaction or 'additivity' was defined as P FICs ¼ 1.
Full suppressive 4-day Peters' test
In vivo tests were performed under the Home Office Animals (Scientific Procedures) Act 1986. The rodent malaria lines used were Plasmodium berghei NY (drug-susceptible), P. berghei P ( primaquine-resistant), P. berghei KFY (sulfadoxine/pyrimethamine-resistant), Plasmodium yoelii NS (chloroquine-resistant), P. yoelii ART (artemisinin-resistant) and Plasmodium chabaudi AS (drug-susceptible). Swiss outbred 20 g male Tuck Farmed White (TFW) albino mice (A. Tuck and Son, Rayleigh, Essex, UK) were kept in specific pathogen-free conditions and fed ad libitum with SDS RM3 expanded diet (supplied by Special Diet Services, Witham, Essex, UK). For subcutaneous administration, artemisone and artesunate were dissolved in 10% DMSO/0.05% Tween 80 (Sigma) in distilled water. For oral administration, compounds were dissolved in standard suspending formula [0.5% sodium carboxymethylcellulose/0.5% benzyl alcohol/ 0.4% Tween 80/0.9% NaCl (all Sigma)]. Mice were infected intravenously with 2 Â 10 6 infected red cells and treated subcutaneously or orally with 0.2 mL of a solution of the test compounds 2 h (day 0) and on days 1, 2 and 3 post-infection. Parasitaemia was determined by microscopic examination of Giemsa-stained blood films taken on day 4. Microscopic counts of blood films from each mouse were processed using GraphPad Prism 4 (GraphPad Software, Inc., CA, USA) and expressed as percentages of inhibition from the arithmetic mean parasitaemias of each group in relation to the untreated group. Dose -response curves were obtained and ED 50 and ED 90 values calculated. The degree of cross-resistance was determined by comparing the activity in the parent and resistant lines using the following formula:
Index of cross-resistanceðI 50=90 Þ ¼ ðED 50 =ED 90 resistant lineÞ ðED 50 =ED 90 parent lineÞ Differences in ED 50 /ED 90 values between treatment groups were analysed by a paired Student's t-test using GraphPad Prism 4 (GraphPad Software, Inc.) and differences considered significant if P , 0.05. Activity correlations between artesunate and artemisone at the ED 50 and ED 90 levels were analysed by Pearson correlation (r) using STATA TM (StataCorp LP). Statistical significance was defined as P , 0.05.
In vivo drug-drug interaction study
Drug interactions of artemisone with mefloquine, chloroquine and clindamycin were investigated in P. berghei NY (drugsusceptible), P. berghei N1100 (mefloquine-resistant) and P. yoelii NS (chloroquine-resistant) lines. Interactions were analysed by the chequerboard method and the dose range for each compound was selected to give a range from an inactive dose to the ED 90 . The ED 90 values obtained with the combination were compared with those of the individual compounds to obtain an isobolar equivalent (IE):
IEs were plotted in isobolograms to visualize the presence of synergism, antagonism or no interaction. Synergy or antagonism was defined when the value of the IE was below or above the line of additivity, respectively.
Results
In vitro anti-P. falciparum activity Artemisone was found to be approximately 10 times more active than artesunate against all the P. falciparum strains tested ( Figure 1 and Table 1 
In vitro drug -drug interactions
The isobolograms obtained with the susceptible 3D7 clone and drug-resistant K1 strain at the IC 50 level are shown in Figure 2 . There were slight antagonistic trends between artemisone and chloroquine, amodiaquine, tafenoquine, atovaquone or pyrimethamine. Additive to slight synergistic interactions were seen with artemisone and mefloquine, lumefantrine or quinine. Isobolograms at the IC 90 levels are shown as Supplementary data [ Figure S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)] and confirm the trends seen at the IC 50 level. In general, a similar profile of interactions was observed between artemisone and artesunate with the antimalarial drugs tested.
In vivo blood schizontocidal activity
Artemisone was tested subcutaneously and orally using the 4-day Peters' test against the drug-susceptible (NY), the primaquine-resistant (P) and sulfadoxine/pyrimethamineresistant (KFY) lines of P. berghei, the chloroquine-resistant (NS) and artemisinin-resistant (ART) lines of P. yoelii NS and the drug-susceptible P. chabaudi AS. The ED 50 and ED 90 values are summarized in 
In vivo drug-drug interactions
In order to complement the information obtained in vitro, drug interactions of artemisone with some standard antimalarials were examined in vivo. Artemisone in combination with mefloquine against the drug-susceptible P. berghei NY and the mefloquine-resistant P. berghei N1100 lines showed a synergistic effect against both resistant and susceptible parasites (Figure 3a and b) . When combined with chloroquine, no interaction against the drug-susceptible P. berghei NY was observed, but a synergistic effect against the chloroquine-resistant line P. yoelii NS was observed (Figure 4a and b) . Artemisone in combination with clindamycin showed an additive to weak synergistic effect against P. berghei NY ( Figure 5 ).
Discussion
In this study, we have demonstrated the superior efficacy of artemisone over artesunate against a broad range of P. falciparum strains with different antimalarial drug-susceptibility profiles and geographical origins. Although some degree of crosssusceptibility was observed between artesunate and artemisone in vivo, the efficacy profile against drug-resistant rodent malaria line highlights the potential of artemisone for use in areas of multidrug-resistant P. falciparum malaria. The enhanced potency of artemisone over artesunate against P. berghei NY (between 4-and 10-fold) correlates with the findings obtained in an in vitro Xenopus laevis oocyte expression system, in which P. berghei SERCA, a primary target for artemisinins, was 36-fold less susceptible to artemisinin than to artemisone. 26 Artemisone and artesunate showed a similar pattern of interactions with standard antimalarials. The slightly antagonistic trend between artemisone and chloroquine, atovaquone or pyrimethamine, and the synergism between artemisone and mefloquine or lumefantrine in vitro concur with previous data obtained with other artemisinins. 21,23,27 -29 In our studies, the interaction of artemisone with lumefantrine was slightly synergistic against the drug-resistant K1 strain. We observed slight antagonism between artemisone or artesunate and tafenoquine against 3D7 and K1 strains, which contrasts with the synergistic effect between tafenoquine and artemisinin against multidrug-resistant isolates reported previously. 30 Similar contrasting results were found with artemisone and artesunate plus amodiaquine, in which antagonism was observed, despite a synergistic interaction between artemisinin and amodiaquine reported previously. 31 These differences may be related to different drug ratios used or varying degrees of drug susceptibility of P. falciparum strains or isolates used in each study.
The synergistic effects observed in vitro with artemisone and mefloquine were reproduced in vivo and were similar to those reported previously for artesunate in combination with mefloquine. 32 The combination of artemisone with chloroquine and with clindamycin had a synergistic effect in vivo, particularly with chloroquine against the chloroquine-resistant P. yoelii NS and less apparent with clindamycin in P. berghei NY. It is likely that the differences observed between the nature of the in vitro and in vivo interactions are related to the pharmacokinetic and metabolic components of the in vivo systems. Mild antagonism in vitro does not justify the rejection of a drug combination, particularly where one of the drugs is rapidly eliminated in vivo. In summary, these results suggest that artemisone may prove useful in areas of multidrug-resistant P. falciparum malaria and will be an important addition to the repertoire of artemisinin derivatives already in use or in development, such as the new trioxolanes. 34 The enhanced antimalarial activity of artemisone will result in low-dose treatment regimens, a reduction in costs and requirement for artemisinin as a natural source with the possibility of using a long-acting blood schizontocide such as mefloquine as partner drug. Artemisone, unlike the carboxylic acid artesunate, should also be compatible with amodiaquine and other basic quinoline antimalarials in fixed formulation combinations. In the light of recently reported reduced in vitro susceptibility of human isolates to artemisinins, 11 the superior efficacy of artemisone when compared with artesunate against a P. yoelii artemisinin-resistant line underlines the potential that artemisone may have to combat artemisinin-resistant P. falciparum in the future.
Further investigation of the effect of artemisone against P. falciparum sexual and liver stages, and other Plasmodium species is relevant to assess its potential in transmission reduction, prophylaxis and efficacy in areas with a high prevalence of mixed infections. 
